Pulse Biosciences Stock Earnings Reports

Pulse Biosciences reported a transformational Q1 2026 quarter driven by clinical and program milestones for its nanosecond Pulsed Field Ablation (nsPFA) platform. Key operational highlights: landmark clinical data from the European feasibility study showing high procedural success and durable pulmonary vein isolation (100% at 6 months by 24-hour Holter of evaluable patients; ~96% at 12 months; ~90% KM freedom from AF/atrial flutter/atrial tachycardia at 1 year); commencement and rapid early enrollment of the U.S. IDE pivotal trial (NANOPULSE-AF) with tightened enrollment timeline now expected to complete in early Q4 2026; strategic refocus and resource allocation to the nPulse Cardiac Catheter program (hiring and leadership additions including a full-time CMO and new COO); ongoing surgical clamp and percutaneous Vybrance programs progressing with CE submission targets (cardiac clamp and Vybrance) and promising feasibility / durability data (surgical PVI success ~94% at ~3 months; Vybrance benign thyroid nodule & PTMC studies progressing). Financials: Q1 revenues were $0.4M, GAAP net loss $18.6M, non-GAAP net loss $16.4M; cash and equivalents of $68.3M as of March 31, 2026 (down $12.4M QoQ). Company completed a $200M shelf registration and maintains an ATM (~$60M available). Management expects cash to fund operations through major 2026 inflection points while deliberately increasing clinical and R&D spend to accelerate pivotal trials and commercialization readiness. Overall message to investors: clinical data provide strong efficacy/safety signals and have prompted prioritization of the high-value AF catheter program with accelerated timelines and leadership hires; balance-sheet and financing programs are in place to support near-term execution, but operating losses and cash burn have increased to support these activities.